▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #673 by analyst upside · 2026-09-27
HYPD
Hyperion DeFi, Inc.
Healthcare · Market Cap $63M · P/E 0x
ANALYST PRICE TARGET
+143.2%
implied upside to consensus target
Current Price $4.04
Consensus Target $9.82
Bull Target $11.2
Bear Target $8.45
Analysts Covering 2
ANALYST CONSENSUS - BUY
Strong Buy
0
Buy
2
Hold
0
Sell
0
52-Week Low $2.34
52-Week High $11.89
YTD Return +12.8%
FUNDAMENTALS
Market Cap $63M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-3.86
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $1M
Profit Margin 474.9%
52-WEEK RANGE
52-Week Low $2.34
52-Week High $11.89
Current Price $4.04
Bear Target $8.45
Bull Target $11.2
● Now $4.04 ● Target $9.82
TRADING DATA
Avg Volume 434K
YTD Return +12.8%
Analyst Count 2
Consensus Buy
Upside to Target +143.2%
Last Updated 2026-09-27

ANALYST SUMMARY

Hyperion DeFi, Inc. (HYPD) is currently trading at $4.04 with a Wall Street consensus price target of $9.82, implying potential upside of 143.2% over the next 12 months. 2 analysts currently cover HYPD, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $11.2, while the most cautious has a target of $8.45.

HYPD operates in the Healthcare sector with a market capitalisation of $63M. The stock is up 12.8% year-to-date and is currently trading near the lower end of its 52-week range of $2.34 – $11.89.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

ELOX +154.5%
Eloxx Pharmaceuticals, Inc.
$52M · P/E 4.3x · Buy
FBIO +119.3%
Fortress Biotech, Inc.
$76M · P/E 0.8x · Buy
DXR +81.7%
Daxor Corporation
$64M · P/E 6.5x · Strong Buy
BTMD +114.1%
biote Corp.
$41M · P/E 8.7x · Buy
BSEM +69.1%
BioStem Technologies, Inc.
$74M · P/E 4.7x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for HYPD, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Cantor Fitzgerald - Reiterated
Overweight → Overweight 2026-09-10 40% win rate (10 calls)
Chardan Capital - Reiterated
Buy → Buy 2026-09-08 33% win rate (6 calls)
Chardan Capital - Reiterated
Buy → Buy 2026-08-13 33% win rate (6 calls)
Cantor Fitzgerald - Reiterated
Overweight → Overweight 2026-08-13 40% win rate (10 calls)
Chardan Capital - Reiterated
Buy → Buy 2026-08-11 33% win rate (6 calls)
Cantor Fitzgerald - Reiterated
Overweight → Overweight 2026-07-01 40% win rate (10 calls)
Chardan Capital - Reiterated
Buy → Buy 2026-06-08 33% win rate (6 calls)
Chardan Capital - Reiterated
Buy → Buy 2026-03-27 33% win rate (6 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
51
out of 100
Coverage depth
8/30
Consensus clarity
16/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →